The good face of Cannabis sativa: cannabidiol

Cannabidiol (CBD) is the second-most common phytocannabinoid found in cannabis plants after tetrahydrocannabinol (THC). Unlike THC, no psychoactive effect has been demonstrated for CBD. Due to its effect on various neurotransmitter systems, it has been tried for the treatment of many physical and psychiatric diseases, considering its neuroprotective and anti-inflammatory properties. In this Editorial, the characteristics of CBD and its place in various psychiatric disorders will be briefly discussed.

Kaynakça

1. Chye Y, Christensen E, Solowij N, Yucel M. The endocannabinoid system and cannabidiol’s promise for the treatment of substance use disorder. Front Psychiatry 2019; 10:63.

2. WHO (World Health Organization). Cannabidiol (CBD). 39th ECDD (Expert Committee on Drug Dependence) Agenda item 5.2. Geneva, 2017. https://www.who.int/medicines/access/ controlled-substances/5.2_CBD.pdf. Accessed [October 2019]

3. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther 2017; 175:133-150.

4. Prud’homme M, Cata R, Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abuse 2015; 9:33-38.

5. White CM. A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacol 2019; 59:923-934.

6. Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, Walsh SL. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 2017; 172:9-13.

7. Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial. Epilepsy Behav 2018; 88:162-71.

8. Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, MacKillop J. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review. Alcohol Clin Exp Res 2019; 43:550-563.

9. Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Hasko G, Mechoulam R, Gao B, Pacher P. Cannabidiol attenuates alcoholinduced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. Sci Rep 2017; 7:12064.

10. Viudez-Martinez A, Garcia-Gutierrez MS, Navarron CM, Morales-Calero MI, Navarrete F, Torres-Suarez AI, Manzanares J. Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol 2018; 23:154-164.

11. Viudez-Martinez A, Garcia-Gutierrez MS, Fraguas-Sanchez AI, Torres-Suarez AI, Manzanares J. Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. Br J Pharmacol 2018; 175:3369-3378.

12. Sabioni P, Le Foll B. Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. F1000Res 2018; 7:173.

13. Garcia-Gutierrez MS, Navarrete F, Viudez-Martinez A, Gasparyan A, Caparros E, Manzanares J. Cannabidiol and Cannabis Use Disorder: In Montoya E, Weiss S (editors). Cannabis Use Disorders. Cham: Springer International Publishing, 2019, 31-42.

14. Solowij N, Broyd SJ, Beale C, Prick JA, Greenwood LM, van Hell H, Suo C, Galettis P, Pai N, Fu S, Croft RJ, Martin JH, Yucel M. Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 2018; 3:21-34.

15. Shannon S, Opila-Lehman J. Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med (Encinitas) 2015; 14:31-35.

16. Crippa JA, Hallak JE, Machado-de-Sousa JP, Queiroz RH, Bergamaschi M, Chagas MH, Zuardi AW. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther 2013; 38:162-164.

17. Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology 2016; 41:1974-1982.

18. Katsidoni V, Anagnostou I, Panagis G. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol 2013; 18:286- 296.

19. Ren Y, Whittard J, Higuera-Matas A, Morris C V, Hurd YL. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 2009; 29:14764- 14769.

20. Mahmud A, Gallant S, Sedki F, D’Cunha T, Shalev U. Effects of an acute cannabidiol treatment on cocaine self-administration and cue-induced cocaine seeking in male rats. J Psychopharmacol 2017; 31:96-104.

21. Lujan MA, Castro-Zavala A, Alegre-Zurano L, Valverde O. Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus. Neuropharmacology 2018; 143:163-175.

22. Karimi-Haghighi S, Haghparast A. Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats. Prog Neuropsychopharmacol Biol Psychiatry 2018; 82:307-313.

23. de Carvalho CR, Takahashi RN. Cannabidiol disrupts the reconsolidation of contextual drug-associated memories in Wistar rats. Addict Biol 2017; 22:742-751.

24. Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, Banks SL, Stinchcomb AL, Weiss F. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacology 2018; 43:2036-2045.

25. Hay GL, Baracz SJ, Everett NA, Roberts J, Costa PA, Arnold JC, McGregor IS, Cornish JL. Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. J Psychopharmacol 2018; 32:1369-1378.

26. Galaj E, Bi GH, Yang HJ, Xi ZX. Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-TH1A and TRPV1 receptor mechanisms. Neuropharmacology 2019; 107740.

27. Morgan CJA, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013; 38:2433-2436.

28. Hindocha C, Freeman TP, Grabski M, Stroud JB, Crudgington H, Davies AC, Das RK, Lawn W, Morgan CJA, Curran HV. Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction 2018; 113:1696-1705.

29. Osborne AL, Solowij N, Babic I, Lum JS, Newell KA, Huang X-F, Weston-Green K. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2019; 95:109666.

30. Jimenez Naranjo C, Osborne AL, Weston-Green K. Effect of cannabidiol on muscarinic neurotransmission in the prefrontal cortex and hippocampus of the poly I:C rat model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2019; 94:109640.

31. Rohleder C, Müller JK, Lange B, Leweke FM. Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence. Front Pharmacol 2016; 7:422.

32. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995; 56:485-486.

33. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2:e94.

34. Bhattacharyya S, Wilson R, Appiah-Kusi E, O’Neill A, Brammer M, Perez J, Murray R, Allen P, Bossong MG, McGuire P. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiatry 2018; 75:1107-1117.

35. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics 2015; 12:825-836.

36. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982; 76:245-250.

37. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993; 7(Suppl.1):82-88.

38. Crippa JA de S, Zuardi AW, Garrido GEJ, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JEC, McGuire PK, Busatto GF. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004; 29:417-426.

39. Crippa JAS, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FLS, Martin-Santos R, Simoes MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JEC. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011; 25:121-130.

40. Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, Curran HV, Morgan CJA. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl) 2013; 226:781-792.

41. Hsiao YT, Yi PL, Li CL, Chang FC. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology 2012; 62:373-384.

42. Soares V, Campos A. Evidences for the anti-panic actions of cannabidiol. Curr Neuropharmacol 2017; 15:291-299.

43. Linge R, Jimenez-Sanchez L, Campa L, Pilar-Cuellar F, Vidal R, Pazos A, Adell A, Diaz A. Cannabidiol induces rapidacting antidepressant-like effects and enhances cortical 5-HT/ glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology 2016; 103:16-26.

44. Shoval G, Shbiro L, Hershkovitz L, Hazut N, Zalsman G, Mechoulam R, Weller A. Prohedonic effect of cannabidiol in a rat model of depression. Neuropsychobiology 2016; 73:123-129.

45. Karl T, Garner B, Cheng D. The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer’s disease. Behav Pharmacol 2017; 28 (2 and 3-Spec Issue):142-160.

46. FDA News Release. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. https://www.fda.gov/news-events/pressannouncements/fda-approves-first-drug-comprised-activeingredient-derived-marijuana-treat-rare-severe-forms. Accessed August 23, 2019.

Kaynak Göster

  • ISSN: 1018-8681
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1984

6.3b 3.7b

Sayıdaki Diğer Makaleler

Psychiatric comorbidities in cases with Duchenne muscular dystrophy: a case series

Ürün ÖZER, Ali Evren TUFAN

Association between fear of missing out in social media and problematic internet use in university students

Hatice AYGAR, Saniye GÖKTAŞ, Sevil AKBULUT ZENCİRCİ, Melike ALAİYE, MUHAMMED FATİH ÖNSÜZ, SELMA METİNTAŞ

Evaluation of resilience, quality of life, and depression in family members of alcohol or substance dependent patients

Güliz ŞENORMANCI, Elif EŞMEN, Çetin TURAN, ÖMER ŞENORMANCI

Validity and reliability of the Turkish version of the Recovery Assessment Scale

Cansu GÜLER, Ayça GÜRKAN

Severity of dissociative experiences and emotion dysregulation mediate the relationship between childhood trauma and Internet addiction symptom severity among young adults

Cüneyt EVREN, Bilge EVREN, Ercan DALBUDAK, MERVE TOPCU, Nilay KUTLU, Jon D. ELHAİ

Methylphenidate and indomethacin induced visual hallucination: a case report

KEMAL UTKU YAZICI, İpek PERÇİNEL YAZICI

Turkish validity and reliability study of the Body Esteem Scale

Emine Sevinç SEVİ TOK, ZÜMRÜT GEDİK

Thiol-disulphide homeostasis in patients with general anxiety disorder and panic disorder

Esra KABADAYI ŞAHİN, Gökçen TURAN, Salim NEŞELİOĞLU, SERDAR SÜLEYMAN CAN, MURAT İLHAN ATAGÜN

Pathological gambling in a patient with Parkinson’s Disease and valproate response

Yıldız DEĞİRMENCİ, Hulusi KEÇECİ

ARID1B gene mutation in a patient with Coffin-Siris syndrome and Autism Spectrum Disorder

Nur Seda GÜLCÜ, ALİ KARAYAĞMURLU